Description

Assay Development & Early Screening

Senectus Therapeutics Ltd is a new venture for CRT. It is founded on a hand-picked consortium of key UK scientists whose research expertise in telomere biology, autophagy and tumour suppression is being utilised to develop innovative drug screening techniques. In conceiving Senectus, the primary objective was to bring together world leading CRUK expertise in mammalian cellular senescence along with new and advanced technologies in cell engineering and imaging to generate a toolbox of high content screening techniques, reagents and tools. Ultimately, the outcome of the initiative will be identification of critical paths for cellular senescence, development of screens for compounds modulating senescence and small molecules and target leads for drug development and pathway manipulation.

Download the PDF of Senectus Therapeutics Limited

For more information please contact

Dr Elisabeth Parker

+44 (0) 20 3469 6300 .(JavaScript must be enabled to view this email address)